Fig. 4

Prognostic value of eIF3i expression in stratified LGG, especially in IDH-mutant LGG. a–h Kaplan–Meier overall survival curves for patients stratified by the respective median expression of eIF3i in the CGGA (a–d) and TCGA (e–h) datasets with astrocytoma, IDH-wildtype (a, e), all IDH-mutant LGGs (b, f), oligodendroglioma, IDH-mutant, 1p/19q codel (c, g) and astrocytoma, IDH-mutant (d, h), respectively. i, j ROC curves showed the predictive efficiencies of eIF3i, WHO grade (II and III) and 1p/19q codeletion status on 3-year and 5-year survival in TCGA (I) and CGGA (J) datasets. k Univariate and multivariate Cox regression analyses of the association between clinicopathological factors (including the eIF3i expression) and overall survival of patients in the CGGA and TCGA datasets